LA JOLLA, Calif., May 26, 2026
MediciNova announced the completion of the Last Patient Last Visit (LPLV) in its Phase 2 MN-001-NATG-202 clinical trial evaluating MN-001 (tipelukast) for the treatment of hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The milestone marks a major step forward for the company’s metabolic disease pipeline, with top-line data expected in the third quarter of 2026.
Phase 2 Trial Targets Liver Fat and Triglycerides
The MN-001-NATG-202 study is a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to evaluate the efficacy and safety of MN-001 (tipelukast) in patients suffering from metabolic complications linked to T2DM. Participants were randomized in a 1:1 ratio to receive either 500 mg/day of MN-001 or placebo over a 24-week treatment period.
The trial’s co-primary endpoints focus on two major metabolic indicators: change in liver fat content, measured through the controlled attenuation parameter (CAP) score, and change in fasting serum triglyceride levels at Week 24. Secondary endpoints include assessments of safety, tolerability, HDL-C, LDL-C, and total cholesterol levels. The study is considered important because patients with T2DM frequently develop dyslipidemia and NAFLD, conditions that significantly increase the risk of cardiovascular disease, liver fibrosis, and metabolic complications.
MN-001 Shows Multi-Mechanism Potential in Fibrosis and Metabolic Disease
Advertisement
MN-001 (tipelukast) is a novel orally bioavailable small-molecule therapy with multiple mechanisms of action targeting inflammation, fibrosis, and lipid metabolism. The drug acts through leukotriene receptor antagonism, phosphodiesterase (PDE 3 and PDE 4) inhibition, and inhibition of the 5-lipoxygenase (5-LO) pathway, which has been linked to the development of fibrosis and chronic inflammatory disease.
Preclinical research has shown that MN-001 suppresses fibrosis-related genes including LOXL2, Collagen Type 1, and TIMP-1, while also reducing inflammatory mediators such as CCR2 and MCP-1. Importantly, the therapy has demonstrated the ability to inhibit triglyceride synthesis in hepatocytes, suggesting potential value in treating fatty liver disease and hypertriglyceridemia.
Recent findings also highlighted that MN-002, the major metabolite of MN-001, significantly improved cholesterol efflux in macrophages by upregulating the transport proteins ABCA1 and ABCG1, mechanisms associated with improved lipid handling and cardiovascular protection. These multi-target effects position MN-001 as a potentially differentiated therapy in the growing market for metabolic liver disease treatments.
Growing Need for NAFLD and T2DM Therapies
The prevalence of NAFLD and metabolic dysfunction-associated liver disease continues to rise globally due to increasing rates of obesity and type 2 diabetes mellitus. Patients with T2DM commonly experience hypertriglyceridemia, elevated LDL cholesterol, and reduced HDL cholesterol, creating a cycle of worsening insulin resistance, liver fat accumulation, and cardiovascular risk.
Because there are still limited approved therapies specifically targeting both NAFLD and diabetic dyslipidemia, successful Phase 2 data from the MN-001 program could strengthen MediciNova’s position in the competitive metabolic disease landscape. The company continues to expand its late-stage pipeline focused on inflammatory, fibrotic, and neurodegenerative diseases, with additional clinical programs involving ALS, progressive multiple sclerosis, Long COVID, and idiopathic pulmonary fibrosis.
With the completion of LPLV now achieved, investors and clinicians will closely watch the upcoming Q3 2026 top-line data release, which may determine the future development path for MN-001 in NAFLD and metabolic disease indications.
Source: MediciNova press release
